Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 33
Filtrar
1.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-30429069

RESUMO

Cervical cancer is the second most common gynecological cancer worldwide. In locally advanced cervical cancer, 18F-FDG PET/CT has become important in the initial staging, particularly in the detection of nodal and distant metastasis, aspects with treatment implications and prognostic value. The aims of this study were to review the role of 18F-FDG PET/CT in uterine cervical cancer, according to the guidelines of the main scientific institutions (FIGO, NCCN, SEGO, SEOM, ESGO, and ESMO) and its diagnostic accuracy compared to conventional radiological techniques, as well as to review the acquisition protocol and its utility in radiotherapy planning, response assessment and detection of recurrence.


Assuntos
Fluordesoxiglucose F18 , Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada , Compostos Radiofarmacêuticos , Neoplasias do Colo do Útero/diagnóstico por imagem , Feminino , Humanos , Metástase Linfática , Estadiamento de Neoplasias , Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada/métodos , Guias de Prática Clínica como Assunto , Neoplasias do Colo do Útero/patologia
2.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-29661653

RESUMO

Bone metastatic disease is the main cause of morbidity / mortality in patients with prostate cancer, presenting frequently as bone pain, pathological fractures or spinal cord compression, which requires early and timely therapy. Although, for the moment, the therapeutic window for its use has not been definitively established, radium-223 (223Ra), an alpha particle emitter, has proved to be an effective therapeutic tool, pre or post-chemotherapy, in patients with castration-resistant prostate cancer with symptomatic bone metastases and absence of visceral metastases, significantly modifying the prognosis of the disease. It is therefore imperative to define the ideal scenarios and the correct protocol for the use of this therapy and thus offer the greatest possible clinical benefit to the patient.


Assuntos
Neoplasias Ósseas/radioterapia , Neoplasias de Próstata Resistentes à Castração/patologia , Rádio (Elemento)/uso terapêutico , Neoplasias Ósseas/secundário , Humanos , Masculino , Dosagem Radioterapêutica
3.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-28941866

RESUMO

Positron emission tomography/computed tomography (PET/CT) with 68Ga-PSMA is a non-invasive diagnostic technique to image prostate cancer with increased prostate-specific membrane antigen (PSMA) expression. PSMA is a transmembrane protein present in all prostatic tissues. Increased PSMA expression is seen in several malignancies, although prostate cancer is the tumour where it presents higher concentrations. Almost all prostate adenocarcinomas show PSMA expression in most of lesions, primary and metastatic. Immunohistochemistry has demonstrated that the expression of PSMA increases in patients with de-differentiated, metastatic or hormone-refractory tumours. Moreover, the expression level of PSMA has a prognostic value for disease outcome. PET measures the three-dimensional distribution of 68Ga-PSMA, producing semi-quantitative images that allow for non-invasive assessment of PSMA expression.


Assuntos
Adenocarcinoma/diagnóstico por imagem , Ácido Edético/análogos & derivados , Radioisótopos de Gálio/farmacocinética , Oligopeptídeos/farmacocinética , Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada/métodos , Neoplasias da Próstata/diagnóstico por imagem , Compostos Radiofarmacêuticos/farmacocinética , Adenocarcinoma/química , Adenocarcinoma/patologia , Adenocarcinoma/terapia , Idoso , Ácido Edético/síntese química , Ácido Edético/farmacocinética , Seguimentos , Isótopos de Gálio , Regulação Neoplásica da Expressão Gênica , Humanos , Masculino , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Oligopeptídeos/síntese química , Prognóstico , Antígeno Prostático Específico/análise , Antígeno Prostático Específico/biossíntese , Antígeno Prostático Específico/genética , Neoplasias da Próstata/química , Neoplasias da Próstata/patologia , Neoplasias da Próstata/terapia , Radiometria , Compostos Radiofarmacêuticos/síntese química , Recidiva , Sensibilidade e Especificidade , Distribuição Tecidual , Carga Tumoral
4.
Rev Esp Med Nucl ; 21(2): 88-92, 2002 Apr.
Artigo em Espanhol | MEDLINE | ID: mdl-11879616

RESUMO

PURPOSE: To establish the clinical effectiveness of 67Ga in lymphoma recurrence. PATIENTS AND METHODS: Thirty-nine patients were assessed on 43 occasions (31 for Hodgkin's disease and 12 for non-Hodgkin's lymphoma) either for a suspected recurrence or to monitor the evolution of the disease. A computed tomography (CT) and a 67Ga whole body scan were performed. Independent observers who did not know the definitive diagnosis performed the CT and 67Ga readings. The gold standard was the biopsy results or the follow-up during a 12 months period. RESULTS: Recurrence was confirmed in 17 cases, while 26 continued to have complete remission. Using 67Ga resulted in true positive (TP), 24 true negative (TN), 2 false positive (FP) and 2 false negative (FN) results with a sensitivity of 0.88 (15/17), specificity of 0.92 (24/26), positive predictive value (PPV) of 0.88 (15/17) and negative predictive value (NPV) of 0.92 (24/26), while CT produced 12 TP, 20 TN, 6 FP and 5 FN, with a sensitivity of 0.7 (12/17), specificity of 0.77 (20/26), PPV of 0.88 (12/18) and NPV of 0.92 (20/25). CONCLUSIONS: 67Ga is a useful indicator and has better diagnostic effectiveness than CT for both the confirmation and exclusion of lymphoma recurrence.


Assuntos
Citratos , Radioisótopos de Gálio , Gálio , Linfoma/diagnóstico por imagem , Recidiva Local de Neoplasia/diagnóstico por imagem , Compostos Radiofarmacêuticos , Tomografia Computadorizada de Emissão de Fóton Único , Adolescente , Adulto , Progressão da Doença , Reações Falso-Negativas , Reações Falso-Positivas , Feminino , Seguimentos , Humanos , Linfoma/diagnóstico , Linfoma/patologia , Masculino , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Valor Preditivo dos Testes , Estudos Retrospectivos , Sensibilidade e Especificidade , Tomografia Computadorizada por Raios X
5.
Rev Esp Med Nucl ; 19(7): 467-71, 2000 Dec.
Artigo em Espanhol | MEDLINE | ID: mdl-11171502

RESUMO

OBJECTIVE: To verify the utility of diuretic renography using 99mTc-MAG3 in the evaluation of the urinary tract obstruction in patients with prenatal diagnosis of hydronephrosis. In a neonate with upper urinary tract dilatation, it is difficult to differentiate a true obstruction from a dilated non-obstructed system. MATERIAL AND METHODS: The retrospective study (january 1993-december 1998) included 40 consecutive patients selected from 181 newborns with a prenatal diagnosis of hydronephrosis. The mean age of the performance of the first renography was 2.6 months. RESULTS: The final diagnosis (once the vesicoureteral reflux was ruled out) was: ureteropelvic junction obstruction (UPJ) 16, megaureter 15, ureterocele 3 and stasis 6. Conservative treatment was applied in most of the patients. Nevertheless, 17 of them needed surgical treatment due to the high risk of the permanent renal damage. CONCLUSIONS: 1) UPJ is the most frequent cause of neonatal hydronephrosis (NH) and consequently, of the request for diuretic renographies. The renography with 99mTc-MAG3 has the greatest influence in the therapeutic decision (identifying who should be operated on and when this should be done), due to the fact that it is the disease with the highest rate of surgical interventions. 2). The surgical indication in NH is based on the diuretic renography parameters and/or on the presence of symptomatology. In our series of surgical patients, none of those who had a differential renal function <20% with regard to the contralateral one showed recuperation after surgery (control 6 months later).


Assuntos
Hidronefrose/diagnóstico por imagem , Diagnóstico Pré-Natal , Renografia por Radioisótopo , Diurese , Feminino , Humanos , Recém-Nascido , Masculino , Gravidez , Estudos Retrospectivos
6.
Rev Esp Med Nucl ; 23(3): 189-92, 2004.
Artigo em Espanhol | MEDLINE | ID: mdl-15153362

RESUMO

We report the case of a 62 year old man diagnosed of alkaptonuria who was referred to our department to undergo bone scintigraphy for polyarthralgia. The patient had a history of pain in lumbar and thoracic spine, right shoulder and left knee. Bone scintigraphy showed multiple joint disease with increased uptake in both shoulders, knees and spine. Higher uptake stood out in painful right shoulder and left knee joints. Ochronotic arthropathy that is developed in alkaptonuric patients is a degenerative joint disease. X-ray studies in this patient showed marked degenerative arthrosis in knees and shoulders, without more intense involvement in the symptomatic joints. Lumbar spine X-rays showed intervertebral disk calcification with disk collapse and fusion of the vertebral bodies with relative sparing of sacroiliac joint, which is a classic feature of ochronotic arthropathy. This case highlights the utility of bone scintigraphy in the evaluation of joint involvement as well as its correlation with clinical course and potential usefulness in the follow-up of this disease.


Assuntos
Alcaptonúria/complicações , Artropatias/diagnóstico por imagem , Artropatias/etiologia , Ocronose/diagnóstico por imagem , Ocronose/etiologia , Humanos , Masculino , Pessoa de Meia-Idade , Cintilografia
13.
Rev. esp. med. nucl. imagen mol. (Ed. impr.) ; 38(1): 59-68, ene.-feb. 2019. ilus, tab
Artigo em Espanhol | IBECS (Espanha) | ID: ibc-182361

RESUMO

El cáncer de cérvix es el segundo cáncer ginecológico en frecuencia a nivel mundial. En tumores localmente avanzados la PET/TC con 18F-FDG tiene un papel relevante en la detección de enfermedad ganglionar y a distancia, factores en los que se basan el tratamiento y el pronóstico de estas pacientes. El objetivo de este trabajo es revisar las indicaciones actuales de la PET/TC con 18F-FDG en el cáncer de cérvix para cada una de las principales sociedades científicas (FIGO, NCCN, SEGO, SEOM, ESGO, ESMO) y la rentabilidad diagnóstica de la prueba comparada con las técnicas radiológicas convencionales, así como el procedimiento y su utilidad en la planificación de la radioterapia, en la valoración de respuesta y en la detección de recidiva


Cervical cancer is the second most common gynecological cancer worldwide. In locally advanced cervical cancer, 18F-FDG PET/CT has become important in the initial staging, particularly in the detection of nodal and distant metastasis, aspects with treatment implications and prognostic value. The aims of this study were to review the role of 18F-FDG PET/CT in uterine cervical cancer, according to the guidelines of the main scientific institutions (FIGO, NCCN, SEGO, SEOM, ESGO, and ESMO) and its diagnostic accuracy compared to conventional radiological techniques, as well as to review the acquisition protocol and its utility in radiotherapy planning, response assessment and detection of recurrence


Assuntos
Humanos , Feminino , Neoplasias do Colo do Útero/diagnóstico por imagem , Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada/métodos , Fluordesoxiglucose F18 , Estadiamento de Neoplasias/métodos , Neoplasias do Colo do Útero/epidemiologia , Infecções por Papillomavirus/epidemiologia , Neoplasias de Células Escamosas/patologia
14.
Rev. esp. med. nucl. imagen mol. (Ed. impr.) ; 37(5): 330-337, sept.-oct. 2018. ilus, tab
Artigo em Espanhol | IBECS (Espanha) | ID: ibc-178231

RESUMO

La enfermedad metastásica ósea es la principal causa de morbimortalidad en pacientes con cáncer de próstata, presentándose frecuentemente como dolor óseo, fracturas patológicas o compresión medular, lo que requiere la instauración de una terapia precoz y oportuna. Aunque, por el momento, no se ha establecido de manera definitiva la ventana terapéutica para su utilización, el radio-223, fármaco emisor de partículas alfa, ha demostrado ser un arma terapéutica eficaz, pre o posquimioterapia, en pacientes con cáncer de próstata resistente a la castración con metástasis óseas sintomáticas y ausencia de enfermedad visceral, modificando de manera significativa el pronóstico de la enfermedad. Resulta, por tanto, imperativo definir los escenarios idóneos y el correcto protocolo para el empleo de esta terapia y así ofrecer el mayor beneficio clínico posible al paciente


Bone metastatic disease is the main cause of morbidity / mortality in patients with prostate cancer, presenting frequently as bone pain, pathological fractures or spinal cord compression, which requires early and timely therapy. Although, for the moment, the therapeutic window for its use has not been definitively established, radium-223 (223Ra), an alpha particle emitter, has proved to be an effective therapeutic tool, pre or post-chemotherapy, in patients with castration-resistant prostate cancer with symptomatic bone metastases and absence of visceral metastases, significantly modifying the prognosis of the disease. It is therefore imperative to define the ideal scenarios and the correct protocol for the use of this therapy and thus offer the greatest possible clinical benefit to the patient


Assuntos
Humanos , Masculino , Neoplasias de Próstata Resistentes à Castração/patologia , Neoplasias Ósseas/radioterapia , Metástase Neoplásica/radioterapia , Compostos Radiofarmacêuticos/metabolismo , Antígeno Prostático Específico/análise
15.
Rev. esp. med. nucl. imagen mol. (Ed. impr.) ; 37(2): 130-138, mar.-abr. 2018. ilus
Artigo em Espanhol | IBECS (Espanha) | ID: ibc-171462

RESUMO

La tomografía por emisión de positrones/tomografía computarizada (PET/TC) con 68Ga-PSMA es una técnica de imagen no invasiva para el estudio del cáncer de próstata con incremento de la expresión del antígeno prostático específico de membrana (prostate-specific membrane antigen, PSMA). El PSMA es una proteína transmembrana presente en todos los tejidos prostáticos. El incremento de la expresión de PSMA está presente en varios tumores, aunque su concentración es más elevada en el cáncer de próstata. Casi todos los adenocarcinomas de próstata muestran expresión de PSMA en la mayoría de las lesiones, tanto primarias como metastásicas. Estudios inmunohistoquímicos han demostrado que la expresión de PSMA está incrementada en pacientes con tumores desdiferenciados, metastásicos u hormonorrefractarios. Más aún, el nivel de expresión del PSMA tiene un valor pronóstico para la evolución de la enfermedad. La tomografía por emisión de positrones proporciona una medida de la distribución tridimensional del 68Ga-PSMA, obteniendo imágenes semicuantitativas que permiten valorar de forma no invasiva la expresión de PSMA (AU)


Positron emission tomography/computed tomography (PET/CT) with 68Ga-PSMA is a non-invasive diagnostic technique to image prostate cancer with increased prostate-specific membrane antigen (PSMA) expression. PSMA is a transmembrane protein present in all prostatic tissues. Increased PSMA expression is seen in several malignancies, although prostate cancer is the tumour where it presents higher concentrations. Almost all prostate adenocarcinomas show PSMA expression in most of lesions, primary and metastatic. Immunohistochemistry has demonstrated that the expression of PSMA increases in patients with de-differentiated, metastatic or hormone-refractory tumours. Moreover, the expression level of PSMA has a prognostic value for disease outcome. PET measures the three-dimensional distribution of 68Ga-PSMA, producing semi-quantitative images that allow for non-invasive assessment of PSMA expression (AU)


Assuntos
Humanos , Neoplasias da Próstata/diagnóstico por imagem , Antígeno Prostático Específico/análise , Compostos Radiofarmacêuticos/análise , Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada/métodos , Gadolínio/análise , Prognóstico , Padrões de Prática Médica
16.
Int J Dermatol ; 46(5): 503-4, 2007 May.
Artigo em Inglês | MEDLINE | ID: mdl-17472683

RESUMO

We report a patient with multiple myeloma associated with primary systemic amyloidosis who had a rapid evolution and a very unusual form of presentation. The association of amyloidosis in patients with multiple myeloma is 15%, and clinically evident mucocutaneous involvement occurs in up to 40% of patients.


Assuntos
Amiloidose/complicações , Meato Acústico Externo/anormalidades , Rouquidão/etiologia , Dermatopatias/etiologia , Amiloidose/diagnóstico , Constrição Patológica/etiologia , Diagnóstico Diferencial , Deformidades Adquiridas da Orelha/etiologia , Feminino , Humanos , Pessoa de Meia-Idade , Mieloma Múltiplo/complicações , Mieloma Múltiplo/diagnóstico
17.
Arthritis Rheum ; 33(7): 1052-5, 1990 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-2142424

RESUMO

Low back pain is the most frequent rheumatologic manifestation of brucellosis. The diagnosis of brucellar sacroiliitis is hampered by the poor specificity of the clinical data and the poor sensitivity of the radiologic data. In this report, we show that scintigraphy not only increases the sensitivity but also allows an earlier diagnosis of disease and permits the detection of osteoarticular brucellar involvement in areas adjacent to the sacroiliac joint.


Assuntos
Dor nas Costas/diagnóstico por imagem , Brucelose/diagnóstico por imagem , Dor nas Costas/etiologia , Brucelose/complicações , Diagnóstico Diferencial , Humanos , Estudos Prospectivos , Cintilografia , Medronato de Tecnécio Tc 99m
18.
Rev Clin Esp ; 194(5): 334-40, 1994 May.
Artigo em Espanhol | MEDLINE | ID: mdl-8059029

RESUMO

The aim of the present work was dual: to study the pulmonary clearance of 99mTC-DTPA (Cl 99mTc-DTPA) in patients suspected (n = 16) of suffering (n = 42) from diffuse interstitial lung disease (DILD) and to compare the technique with other classic clinical methods. Results showed that pulmonary clearance of Cl 99mTc-DTPA is of little value in patients with DILD who smoke, although in non-smokers the technique serves as a complementary test to other classic methods and detects alterations in epithelial permeability not only in cases of confirmed DILD but also in other cases with suspicion of DILD and normal radiology.


Assuntos
Doenças Pulmonares Intersticiais/diagnóstico por imagem , Pentetato de Tecnécio Tc 99m , Adulto , Barreira Alveolocapilar , Feminino , Humanos , Doenças Pulmonares Intersticiais/complicações , Doenças Pulmonares Intersticiais/metabolismo , Masculino , Pessoa de Meia-Idade , Cintilografia , Valores de Referência , Fumar/metabolismo , Pentetato de Tecnécio Tc 99m/farmacocinética
19.
J Eur Acad Dermatol Venereol ; 18(3): 310-3, 2004 May.
Artigo em Inglês | MEDLINE | ID: mdl-15096141

RESUMO

In the last years, granulocyte and granulocyte-macrophage colony-stimulating factors (G-CSF and GM-CSF) are being increasingly used and several cutaneous eruptions have been reported in relation to these treatments. In 1991 Horn et al. described three patients with maculopapular eruption that paralleled the time of infusion of GM-CSF. Two of the cases showed an increase in the number and size of macrophages in the biopsy specimen. Since then, several cases have been reported showing this histopathological alteration that has been considered characteristic of reaction to G-CSF or GM-CSF. Although maculopapular eruption with enlarged macrophages can appear after chemotherapy treatment, we have found that the presentation of this eruption after the beginning of cytokine treatment is suggestive of the involvement of G-CSF and GM-CSF in the eruption. We described eight cases of patients treated with G-CSF or GM-CSF that developed maculopapular eruptions with enlarged macrophages.


Assuntos
Toxidermias/etiologia , Toxidermias/patologia , Exantema/induzido quimicamente , Exantema/patologia , Fator Estimulador de Colônias de Granulócitos/efeitos adversos , Fator Estimulador de Colônias de Granulócitos e Macrófagos/efeitos adversos , Adulto , Biópsia por Agulha , Toxidermias/tratamento farmacológico , Exantema/tratamento farmacológico , Feminino , Fator Estimulador de Colônias de Granulócitos/uso terapêutico , Fator Estimulador de Colônias de Granulócitos e Macrófagos/uso terapêutico , Neoplasias Hematológicas/tratamento farmacológico , Neoplasias Hematológicas/patologia , Humanos , Imuno-Histoquímica , Macrófagos/patologia , Masculino , Pessoa de Meia-Idade , Prognóstico , Estudos Retrospectivos , Medição de Risco , Índice de Gravidade de Doença , Esteroides/uso terapêutico , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA